Medscape5d
New Trials in Breast Cancer: Could Your Patient Benefit?
One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Cure Today6d
Postsurgical Keytruda Plus Chemo May Benefit Patients With dMMR Endometrial Cancer
Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...
MedPage Today4d
Survival Win for Pembrolizumab in Early Triple-Negative Breast Cancer
After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...
Medscape4d
Pembrolizumab Plus Chemoradiotherapy Provides Significant Survival Benefit in Cervical Cancer
BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...
The New England Journal of Medicine6d
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...
Cancer Therapy Advisor5d
Perioperative Pembrolizumab Improves OS in High-Risk TNBC
Source: Getty Images Updated data support the use of perioperative pembrolizumab as part of standard care for patients with high-risk, early TNBC, according to Peter Schmid, MD, PhD. At 5 years ...
Targeted Oncology3d
FDA Approves Frontline Pembrolizumab/Chemotherapy in Advanced Mesothelioma
The FDA approved the frontline combination of pembrolizumab (Keytruda) and chemotherapy in patients with unresectable advanced or metastatic malignant pleural mesothelioma. This approval is supported ...
Targeted Oncology6d
Neoadjuvant and Adjuvant Pembrolizumab Extends Survival in Early-Stage TNBC
In KEYNOTE-522, treatment with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, led to improvements in overall survival among patients with triple-negative breast cancer ...
The New England Journal of Medicine6d
NEJM at ESMO — Overall Survival with Pembrolizumab in Early-Stage Triple- Negative Breast Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.